Harris Vaccines

Harris Vaccines was a biotechnology company specializing in the development and commercialization of rapidly deployable vaccines for the animal health industry. Utilizing its proprietary SirraVax RNA particle technology, the company focused on addressing emerging infectious diseases in livestock, most notably producing the first conditionally licensed vaccine for Porcine Epidemic Diarrhea virus (PEDv). The company's platform allowed for the rapid creation of herd-specific vaccines by inserting genetic sequences of specific pathogens into a standardized production system. In 2015, Harris Vaccines was acquired by Merck Animal Health, integrating its advanced vaccine technologies into Merck's global portfolio.